Skip to content
Mesothelioma.net
phone iconCall1-800-692-8608 chat icon Chat 24/7 Live Chat
Menu
  • Malignant Mesothelioma
    • About Mesothelioma
      • How to Survive Mesothelioma
      • 100 Questions & Answers about Mesothelioma (Free Book)
      • Symptoms
      • Diagnosis
      • Prognosis
      • Life Expectancy
    • Types
      • Pleural
      • Peritoneal
      • Epithelioid
      • Sarcomatoid
      • Biphasic
    • Stages
      • Stage 1
      • Stage 2
      • Stage 3
      • Stage 4
    • Additional Information
      • Causes
      • Asbestos and Its Dangers
      • Facts
      • Support
      • Financial Compensation
      • FREE Mesothelioma Packet
  • Treatment
    • Treatment Options
      • Surgery
      • Chemotherapy
      • Radiation Therapy
      • Multimodal Therapy
      • Medications
      • Palliative Treatment
    • Find Top Doctors
      • Doctors
      • Treatment Centers
      • Treatment & Doctors Near You
      • New Treatments
      • Care Providers
      • Clinical Trials
      • Costs
  • Asbestos Trusts
  • Compensation
  • Veteran Assistance
    • Mesothelioma and Veterans
      • VA Claims for Mesothelioma
      • Vietnam Veterans
    • Military Branches and Asbestos
      • Navy Veterans
      • Navy Ships
      • Marine Corps Veterans
      • Army Veterans
      • Air Force Veterans
      • U.S. Coast Guard
  • Surviving Mesothelioma
  • About Us / Contact

FDA Approves Combination Immunotherapy Treatment for Mesothelioma

Published on October 05, 2020

For the first time in sixteen years, the U.S. Food and Drug Administration (FDA) has given its approval for a new, systemic treatment for malignant mesothelioma. The remarkable move came after the use of a combination of nivolumab (Opdivo) and ipilimumab (Yervoy) treatments provided a more than twenty percent improvement in overall survival for patients who were not eligible for surgery.

Opdivo and Yervoy Extend Overall Survival

Though there have been numerous reports of success in the use of the two monoclonal antibodies against malignant pleural mesothelioma, the FDA approval of the combination still caught the medical world by surprise. 

The two medications work by enhancing T-cell functions and helping them decrease the rate of malignant mesothelioma tumor growth. In a randomized, open-label trial of over 600 patients diagnosed with unresectable, untreated malignant pleural mesothelioma, patients provided with IV infusions of nivolumab every two weeks and of ipilimumab every 6 weeks lived a median of four months longer than those who had been treated with a combination of platinum chemotherapy drugs.

Four More Months of Survival for Malignant Pleural Mesothelioma Patients

In the life of a patient diagnosed with malignant pleural mesothelioma, four months is extremely significant. Speaking of the agency’s decision to provide a mesothelioma drug with approval for the first time in sixteen years, Richard Pazdur, MD, director of the FDA’s Oncology Center of Excellence and acting director of the Office of Oncologic Diseases in the FDA’s Center for Drug Evaluation and Research said “Today’s approval of nivolumab plus ipilimumab provides a new treatment that has demonstrated an improvement in overall survival for patients with malignant pleural mesothelioma. In 2004, FDA approved pemetrexed in combination with cisplatin for this indication, and now patients have an important, additional treatment option after more than a decade with only one FDA-approved drug regimen.”

For patients diagnosed with malignant pleural mesothelioma and not eligible for surgical removal of their tumors, the combination treatment offers new hope for a bit more time with family and friends. Though the treatment does have adverse side effects, they are relatively mild when compared to chemotherapy, and include fatigue, musculoskeletal pain, rash, diarrhea, dyspnea, nausea, decreased appetite, cough, and pruritis. Ipilimumab is known to cause immune-mediated side effects, including inflammation of healthy organs such as the lungs, colon, liver, endocrine glands, and kidneys.

For more information on facilities offering this innovative medical treatment, contact the Patient Advocates at Mesothelioma.net today at 1-800-692-8608.

FREE Mesothelioma Packet

Written by Terri Oppenheimer

Terri Heimann Oppenheimer
Terri Heimann Oppenheimer is the head writer of our Mesothelioma.net news blog. She graduated from the College of William and Mary with a degree in English. Terri believes that knowledge is power and she is committed to sharing news about the impact of mesothelioma, the latest research and medical breakthroughs, and victims’ stories.

Learn more about and contact Terri
  • Malignant Mesothelioma
    • Treatment
    • Asbestos Trusts
  • Compensation
    • Veteran Assistance
    • Surviving Mesothelioma
  • FREE Mesothelioma Packet
    • Mesothelioma News
    • About Us / Contact
  • Privacy Policy
    • Disclaimer
    • Editorial Guidelines and Standards
This website is certified by Health On the Net Foundation. Click to verify. This site complies with the HONcode standard for trustworthy health information: verify here.
The information provided by Mesothelioma.net is not a substitute for professional medical advice, diagnosis or treatment.

Mesothelioma.net

5430 LBJ Freeway Suite 1200
Dallas, Texas 75240

Serving mesothelioma victims nationwide

1-800-692-8608

  • facebook
  • twitter
© 2022 Mesothelioma.net